Home › Diffuse groot-B-cel lymfoom › Texas › Houston
Diffuse groot-B-cel lymfoom klinische studies in Houston, TX
17 studies voor Diffuse groot-B-cel lymfoom zoeken deelnemers op locaties in en rond Houston (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruterenFase 2
- MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruterenObservatieonderzoek
- Texas Children's Hospital, Houston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruterenFase 1/2
- Md Anderson Cancer Center, Houston
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
RekruterenFase 3
- Houston Methodist Cancer Center ( Site 0154), Houston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RekruterenFase 1
- Baylor College of Medicine, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruterenFase 1
- MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekruterenFase 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RekruterenFase 1
- Md Anderson Cancer Center, Houston
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
RekruterenFase 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruterenFase 1/2
- University of Texas MD Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruterenFase 3
- MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RekruterenFase 1
- The University of TX MD Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RekruterenFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruterenFase 1
- MD Anderson Cancer Center, Houston
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruterenFase 1
- MD Anderson Cancer Center, Houston
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
RekruterenFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Study of NX-1607 in Adults With Advanced Malignancies
RekruterenFase 1
- MD Anderson Cancer Center, Houston
Diffuse groot-B-cel lymfoom studies in andere steden
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Los Angeles, CA17 studies
- Boston, MA16 studies
- Milwaukee, WI16 studies
- Portland, OR15 studies
- Nashville, TN15 studies
- Philadelphia, PA15 studies
- Durham, NC14 studies
- Dallas, TX13 studies
- Seattle, WA12 studies
Andere studies in Houston
- Niet-kleincellige longkanker145 studies
- Borstkanker126 studies
- Kanker (alle vormen)121 studies
- Metastatische kanker104 studies
- Colorectale kanker102 studies
- Eierstokkanker89 studies
- Acute myeloïde leukemie85 studies
- Longkanker78 studies
- Prostaatkanker76 studies
- Endometriumkanker68 studies
- Aldermeesklierkanker61 studies
- Melanoom59 studies
Van ClinicalTrials.gov, gegevens opgehaald op 3 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.